Skip to content
OpenCapital
Get started

Innovate VATE Life Sciences — Investments

Other segment segments

Infrastructure
$0—
Spectrum
$0—

Other financials

Income statement

See full
Revenue$364.8M+33.0%
Gross profit$53.5M+17.6%
Operating income$10.0M+194%
Net income-$16.8M+31.4%
EPS (diluted)-$1.29+31.7%

Balance sheet

See full
Cash & equivalents$134.6M+297%
Total debt$1.4B+11.6%
Total equity-$256.3M-25.5%
Total assets$936.8M+7.9%

Cash flow

See full
Operating cash flow$45.5M+423%
CapEx$200.0K-95.7%
Free cash flow$45.3M+341%

Valuation

See full
Market cap$254.69M+274%

Where this comes from

Reported directly by Innovate in its filing.

Tagged under the XBRL concept us-gaap:Investments.

The official record: Innovate’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innovate's life sciences — investments.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innovate's life sciences — investments?
Innovate (VATE) reported life sciences — investments of $1.8M in Q1 2026.
How has Innovate's life sciences — investments changed year-over-year?
Innovate's life sciences — investments decreased by 0.0% year-over-year, from $1.8M to $1.8M.
What is the long-term trend for Innovate's life sciences — investments?
Over 3 years (2022 to 2025), Innovate's life sciences — investments has grown at a -44.2% compound annual growth rate (CAGR), from $41.4M to $7.2M.
What does life sciences — investments mean?
Captures the total value of capital deployed by the Life Sciences segment into assets or ventures intended to generate future returns. This reflects the strategic commitment of resources to expand the segment's market footprint or technological capabilities.